Jessica Walters

Explore how neuromelanin-sensitive MRI noninvasively tracks long-term dopamine and noradrenaline system changes.

Low soluble α2δ‑1 disrupts brain excitation‑inhibition balance in schizophrenia.

Round on the latest news in psychiatry from the last week.

New data shows stable symptoms when switching from atypical antipsychotics to Cobenfy using cross-titration.

AI video screening spots early tardive dyskinesia signs, prompting clinical follow-up and treatment.

Study links schizophrenia’s earlier onset to higher genomic deletion CNV burden, showing future potential for personalized care.

Round on the latest news in psychiatry from the last week.

Emerging student researchers share their award-winning neuroscience and psychiatry projects.

Data suggest PBFT02 therapy boosts progranulin and slows neurodegeneration markers in early FTD.

Faster aging may be linked to schizophrenia, according to new research.

Shared pathophysiology between Alzheimer disease and autism may expand diagnosis and treatment opportunities.

A pharma expert and clinician shares perspectives on developing treatments.

BPL-003 phase 2a part 2 results show reductions in depression symptoms.

Experts share how roluperidone provides a new opportunity in the schizophrenia treatment landscape.

New analysis links traumatic brain injury to later psychosis, prompting long-term screening and follow-up.

A novel form of agomelatine shows positive initial results.

Further data shared on LB-102 for schizophrenia.

Tazbentetol interim results show improvement in schizophrenia symptoms.

AD/PD 2026 highlights oral blarcamesine preserving brain volume and IV lecanemab sustaining use while clearing amyloid-beta.

Intranasal BPL-003 shows rapid, sustained depression relief in treatment-resistant patients.

Remote QbCheck testing tracks ADHD treatment progress.

Cytisinicline helps smokers quit—even after multiple failed attempts—showing reduced nicotine dependence in phase 3 trials.

Early psychosis screening in teens and young adults helps catch overlooked symptoms sooner.

FDA clears Bysanti, a novel atypical antipsychotic for acute bipolar I and schizophrenia, leveraging Fanapt data; US launch planned 2026.

APSARD 2026 highlights: stimulant safety vs substance use, ADHD in pregnancy, and new nonstimulants.

FDA feedback for CYC-126: anesthetic therapy with live EEG guidance aims to deliver precise relief for treatment-resistant depression.

IV DMT psychedelic SPL026 reduces major depression in phase 2a.

FDA reviews INmune Bio’s biomarker-enriched Phase 2b/3 plan for XPro1595.

Brief interpersonal therapy in pregnancy sharply lowers depression and postpartum relapse for a year—offering clinicians a fast, safe option.